Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy-Treated NSCLC
2008-004691-44Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BMS-690514 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival (PFS). Started Feb 2009; status: terminated.
02
Drugs
BMS-690514
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-004691-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004691-44.